25,000 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by Bamco Inc. NY

Bamco Inc. NY acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 25,000 shares of the company’s stock, valued at approximately $1,183,000.

A number of other institutional investors and hedge funds have also bought and sold shares of KYMR. Values First Advisors Inc. bought a new position in shares of Kymera Therapeutics during the 3rd quarter worth $61,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares in the last quarter. Comerica Bank grew its holdings in Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new position in Kymera Therapeutics during the 2nd quarter valued at about $139,000. Finally, Virtu Financial LLC bought a new stake in shares of Kymera Therapeutics in the 1st quarter valued at about $207,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research note on Monday, August 26th. Stephens began coverage on Kymera Therapeutics in a report on Monday, November 18th. They issued an “overweight” rating and a $65.00 price target on the stock. Oppenheimer boosted their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Monday, September 9th. Finally, Guggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $53.40.

Kymera Therapeutics Trading Down 1.7 %

Shares of Kymera Therapeutics stock opened at $46.91 on Wednesday. The firm’s 50 day simple moving average is $46.66 and its two-hundred day simple moving average is $42.43. The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of -20.05 and a beta of 2.16. Kymera Therapeutics, Inc. has a 12-month low of $20.32 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. During the same period in the prior year, the firm earned ($0.90) EPS. The firm’s revenue was down 20.9% on a year-over-year basis. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 15.82% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.